9 completed, 6 recruiting, 2 terminated, 2 unknown. 21 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 9, Recruiting 6, Terminated 2, Unknown 2, Withdrawn 2 |
| Phase 2 | 9 | Completed 4, Recruiting 3, Unknown 2 |
Follow folfirinox: new trials by email Literature Review of folfirinox trials Research Report on folfirinox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) FLOT, FOLFOX, FOLFIRI - Gastroesophageal Adenocarcinoma | Phase 1 | Recruiting | University of California, Irvine | 20 | 2025-06-27 | 2026-03-10 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Pembrolizumab, Folfirinox, SABR - Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 66 | 2024-09-23 | 2026-02-13 |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Spevatamig (PT886), Paclitaxel, Gemcitabine - Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 350 | 2023-03-15 | 2026-09-28 |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors IBI343, FOLFIRINOX/mFOLFIRINOX, mFOLFOX - Locally Advanced Unresectable or Metastatic Solid Tumors | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 470 | 2022-10-26 | 2026-05-04 |
| FOLFIRINOX + NIS793 in Pancreatic Cancer FOLFIRINOX, Oxaliplatin, Leucovorin - Pancreas Cancer, Metastatic Pancreatic Cancer | Phase 1 | Terminated | Colin D. Weekes, M.D., PhD | 4 | 2022-08-09 | 2025-11-18 |
| CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab CEND-1, Panitumumab, Folfirinox - Colon Cancer, Pancreas Cancer | Phase 1 / Phase 2 | Unknown | Anup Kasi | 50 | 2021-10-20 | 2024-12-17 |
| A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma CAN04, FOLFIRINOX - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | Cantargia AB | 25 | 2021-07-19 | 2023-06-29 |
| ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study ABTL0812, Folfirinox, Placebo - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Ability Pharmaceuticals SL | 150 | 2021-05-06 | 2024-03-18 |
| Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Eryaspase, FOLFIRINOX - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | Georgetown University | 19 | 2020-12-02 | 2025-06-11 |
| Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma FOLFIRI, FOLFIRINOX, TriSalus Infusion System - Pancreatic Adenocarcinoma | Phase 1 | Withdrawn | Roger Williams Medical Center | 2019-12-23 | 2021-06-01 | |
| Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer PD-L1/CTLA4 BsAb, GP, FOLFIRINOX - Locally Advanced and Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Changhai Hospital | 60 | 2019-11-26 | 2023-09-01 |
| Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer Folfirinox + regorafenib - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 13 | 2019-05-14 | 2026-02-27 |
| Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma Irreversible Electroporation (IRE), Gemcitabine, FOLFIRINOX - Pancreas Cancer | Phase 1 | Recruiting | University of Louisville | 20 | 2018-05-30 | 2025-10-29 |
| A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer FOLFIRINOX or gemcitabine/abraxane, SBRT - Pancreatic Cancer | Phase 1 | Completed | University of Colorado, Denver | 14 | 2016-11-17 | 2022-12-19 |
| Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study FOLFIRINOX (oxaliplatin, leucovorin, irinotecan) - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Terminated | University of Chicago | 1 | 2016-06-28 | 2019-03-19 |
| Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma FOLFIRINOX, Electroporation - Pancreatic Adenocarcinoma | Phase 1 | Withdrawn | The University of Texas Health Science Center, Houston | 2015-10-01 | 2018-10-17 | |
| First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. GEMBRAX, FOLFIRINOX - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | Institut du Cancer de Montpellier - Val d'Aurelle | 78 | 2013-09-24 | 2020-12-31 |
| LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan - Pancreatic Cancer | Phase 1 | Completed | Massachusetts General Hospital | 39 | 2011-12-01 | 2020-08-04 |
| Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Gemcitabine, nab-paclitaxel, FOLFIRINOX - Stage IV Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Pancreatic Cancer Research Team | 60 | 2011-11-01 | 2016-08-18 |
Showing 20 of 21. Sign in to see all of them.
Pancreatic Neoplasms (12) · Adenocarcinoma (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Neoplasms (1) · Neoplasms, Basal Cell (1)
Institut du Cancer de Montpellier - Val d'Aurelle (2) · Ability Pharmaceuticals SL (1) · Amsterdam UMC, location VUmc (1) · Andrew Ko (1) · Anup Kasi (1) · Cantargia AB (1) · Changhai Hospital (1) · Colin D. Weekes, M.D., PhD (1) · Georgetown University (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Massachusetts General Hospital (1) · Pancreatic Cancer Research Team (1) · Phanes Therapeutics (1) · Roger Williams Medical Center (1) · The University of Texas Health Science Center, Houston (1)
United States (15) · France (4) · China (2) · Spain (2) · Australia (1) · Israel (1) · Netherlands (1)
Andrew Ko, M.D. (1) · Antoine Adenis, MD (1) · Anup Kasi, MD (1) · Ashwin Somasundaram, MD (1) · Colin D Weekes, MD, PHD (1) · Derek L West, MD, MS (1) · Farshid Dayyani, MD,PhD (1) · Gang Jin, Doctor (1) · Hedy Kindler, M.D. (1) · Ignacio Garcia-Ribas, MD, PhD (1) · Jeffery W Clark, MD (1) · Marc Cortal (1) · Marcus S Noel, MD (1) · Ramesh K Ramanathan, MD (1)
PMID 32681477, PMID 35293148, PMID 38987363, PMID 40670773
2023 (1)